Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.56 |
| ▸ | CTSD | P07339 | 14/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546165 | 1.00 | BACE1 (0.56) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL8411137 | 0.92 | BACE1 (0.48) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7541503 | 0.90 | CTSD (0.47) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL8412199 | 0.90 | BACE1 (0.48) | BACE1CTSDMCHR1DDB1CRBN | |
| SCHEMBL7536828 | 0.90 | BACE1 (0.46) | BACE1CTSDMCHR1 | |
| SCHEMBL13407674 | 0.90 | BACE1 (0.57) | BACE1CTSDPRMT5WDR77 | |
| SCHEMBL7538807 | 0.90 | BACE1 (0.57) | BACE1CTSDPRMT5WDR77 | |
| SCHEMBL7540242 | 0.89 | BACE1 (0.45) | BACE1CTSDMCHR1 | |
| SCHEMBL8412486 | 0.88 | BACE1 (0.44) | BACE1CTSDMCHR1 | |
| SCHEMBL7539290 | 0.88 | MCHR1 (0.48) | BACE1CTSDMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700603-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700603-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |